Chemours prices $700M 7.875% senior notes due 2034
The Chemours Company filed a Form 8-K to report a private debt financing.
Rhea-AI Filing Summary
The Chemours Company filed a Form 8-K to report a private debt financing. The company launched and priced an upsized offering of $700,000,000 aggregate principal amount of 7.875% senior unsecured notes due 2034, increased from a previously announced $600,000,000 offering size.
The notes mature on March 15, 2034 and will pay interest semi-annually on March 15 and September 15, starting September 15, 2026. Chemours intends to use the net proceeds to redeem its outstanding 5.375% senior notes due 2027 and partially redeem its outstanding 5.750% senior notes due 2028. The notes are being sold in a private offering to qualified institutional buyers under Rule 144A and to certain non-U.S. investors under Regulation S.
Positive
- None.
Negative
- None.
Insights
Chemours refinances nearer-term notes with new 2034 debt.
Chemours is issuing $700,000,000 of new senior unsecured notes due 2034 at a coupon of 7.875%, upsized from an initial $600,000,000 target. The stated intent is to redeem 5.375% notes due 2027 and partially redeem 5.750% notes due 2028.
This transaction shifts portions of the company’s debt maturities further into the future while keeping the instruments unsecured and guaranteed by certain subsidiaries. Actual impact on interest expense and leverage will depend on the exact amounts of 2027 and 2028 notes redeemed, which are not detailed in this excerpt.
The offering is limited to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S, with closing expected on March 12, 2026 subject to customary conditions. Subsequent company filings may provide more detail on the completed redemptions and resulting debt profile.
8-K Event Classification
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Chemours (CC) announce in its February 26, 2026 Form 8-K?
How large is Chemours’ new senior notes offering and what is the interest rate?
When do Chemours’ new 7.875% senior notes due 2034 mature and pay interest?
How will Chemours (CC) use the net proceeds from the $700 million notes offering?
To whom are Chemours’ new 2034 senior notes being offered?
Was the Chemours 2034 notes offering changed from the original plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported)
(Exact Name of Registrant as Specified in Its Charter)
|
|
|||
(State or Other Jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
Of Incorporation) |
|
File Number) |
|
Identification No.) |
(Address of principal executive offices)
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Exchange on Which Registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company |
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
|
☐ |
Item 8.01 Other Events.
On February 26, 2026, The Chemours Company issued press releases announcing the launch and pricing of its offering of $700,000,000 aggregate principal amount of 7.875% senior unsecured notes due 2034 in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended. The offering size was increased from the previously announced offering size of $600,000,000 aggregate principal amount of notes.
A copy of the foregoing press releases are attached hereto as Exhibits 99.1 and 99.2 and are incorporated into this Item 8.01 by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Launch Press Release, dated as of February 26, 2026, issued by The Chemours Company.
Exhibit 99.2 Pricing Press Release, dated as of February 26, 2026, issued by The Chemours Company.
104 Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THE CHEMOURS COMPANY |
||
|
||
By: |
|
/s/ Shane Hostetter |
|
|
Shane Hostetter |
|
|
Senior Vice President, Chief Financial Officer |
Date: |
|
February 26, 2026 |
EXHIBIT 99.1
The Chemours Company Announces Private Offering of $600,000,000 of Senior Notes Due 2034
Wilmington, Del., February 26, 2026 – The Chemours Company (“Chemours”) (NYSE: CC) today announced that it intends to offer $600,000,000 aggregate principal amount of new senior notes due 2034 (the “Notes”), subject to market and other conditions. The Notes will be senior unsecured obligations of Chemours and will be guaranteed by a subsidiary of Chemours. Chemours intends to use the net proceeds from the offering to fund the redemption of its outstanding 5.375% senior notes due 2027 and to fund the redemption or repurchase of a portion of its outstanding 5.750% senior notes due 2028.
The Notes and related guarantees are being offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), or outside the United States to non-U.S. persons in compliance with Regulation S under the Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes and related guarantees. Any offers of the Notes and related guarantees are being made only by means of a private offering memorandum.
The Notes and related guarantees have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries.
1
EXHIBIT 99.1
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the offering of Notes and Chemours’ intended use of the net proceeds therefrom, which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the ability of Chemours to complete the offering on favorable terms, if at all, and general market conditions which might affect the offering. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours’ control. Matters outside Chemours’ control, including general economic conditions, geopolitical conditions, changes in laws and regulations in the United States or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect Chemours’ business and operations and may or may continue to hinder Chemours’ ability to provide goods and services to customers, cause disruptions in Chemours’ supply chains such as through strikes, labor disruptions or other events, adversely affect Chemours’ business partners, significantly reduce the demand for Chemours’ products, adversely affect the health and welfare of Chemours’ personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include whether the offering of Notes is completed and other risks, uncertainties and other factors discussed in Chemours’ filings with the U.S. Securities and Exchange Commission, including in Chemours’ Annual Report on Form 10-K for the year ended December 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.
CONTACTS:
INVESTORS
Brandon Ontjes
Vice President, Investor Relations
+1.302.773.3309
investor@chemours.com
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
media@chemours.com
2
EXHIBIT 99.2
The Chemours Company Announces Upsizing and Pricing of Private Offering of $700,000,000 of 7.875% Senior Notes Due 2034
WILMINGTON, Del., February 26, 2026 -- The Chemours Company (Chemours) (NYSE: CC) today announced the pricing of its previously announced private offering of $700,000,000 aggregate principal amount of new 7.875% senior notes due 2034 (the “Notes”). The offering size was increased from the previously announced offering size of $600,000,000 aggregate principal amount of Notes. The Notes will bear interest at 7.875% per annum and mature on March 15, 2034. Interest on the Notes will be payable semi-annually on March 15 and September 15 of each year, beginning on September 15, 2026. The Notes will be senior unsecured obligations of Chemours and will be guaranteed by certain of its subsidiaries. The offering is expected to close on March 12, 2026, subject to customary closing conditions.
Chemours intends to use the net proceeds from the offering to fund the redemption of its outstanding 5.375% senior notes due 2027 and the partial redemption of its outstanding 5.750% senior notes due 2028.
The Notes and related guarantees were offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), or outside the United States to non-U.S. persons in compliance with Regulation S under the Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes and related guarantees.
The Notes and related guarantees have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries.
EXHIBIT 99.2
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the closing of the offering of Notes and Chemours’ intended use of the net proceeds therefrom, which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the ability of Chemours to satisfy the conditions to closing the offering and general market conditions which may impact the closing of the offering. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours’ control. Matters outside Chemours’ control, including general economic conditions, geopolitical conditions, changes in laws and regulations in the United States or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect Chemours’ business and operations and may or may continue to hinder Chemours’ ability to provide goods and services to customers, cause disruptions in Chemours’ supply chains such as through strikes, labor disruptions or other events, adversely affect Chemours’ business partners, significantly reduce the demand for Chemours’ products, adversely affect the health and welfare of Chemours’ personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include whether the offering of Notes is completed and other risks, uncertainties and other factors discussed in Chemours’ filings with the U.S. Securities and Exchange Commission, including in Chemours’ Annual Report on Form 10-K for the year ended December 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.
CONTACTS:
INVESTORS
Brandon Ontjes
Vice President, Investor Relations
+1.302.773.3309
investor@chemours.com
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
media@chemours.com